C1orf122 was upregulated in HCC patients and correlated with poor survival outcome. (IMAGE)
Caption
(A) The abundance of C1orf122 in HCC and normal tissues was assessed using data from TCGA. (B) C1orf122 protein expression in seven pairs of tumor tissues (T) and matching non-cancerous tissues (N) as determined by Western blotting. (C) Immunohistochemistry labelling was performed to assess C1orf122 expression in HCC tissues and adjacent tissues. (D) qRT-PCR and Western blot experiments were performed to measure the levels of C1orf122 in THLE-2 cells and five HCC cell lines. (E) Nude mice were administered and the subcutaneous implants of HepG2 cells were infected with either sg-Control or sg-C1orf122. On day 48 post-implantation, the tumors were collected and photographed, and the tumor growth was tracked. Data (tumor weight and volume data) are expressed as the mean ± SD (n = 4). (F) The association of C1orf122 levels with the overall survival of patients with HCC was determined by the Kaplan-Meier survival analysis on the GEPIA database. **P <0.01, ***P < 0.001.
Credit
Jing Cai, Li Rong, Runzhi Wang, Zaikuan Zhang, Haiming Sun, Juan Chen, Dunchu Weng, Xinyi Li, Xiaosong Feng, Peiyi Lin, Shengming Xu, Zhihong Jiang, Yajun Xie, Qin Zhou
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND